サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1742781

口腔咽頭カンジダ症の世界市場

Oropharyngeal Candidiasis

出版日
ページ情報
英文 462 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.90円
口腔咽頭カンジダ症の世界市場
出版日: 2025年06月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 462 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

口腔咽頭カンジダ症の世界市場は2030年までに4億8,920万米ドルに達する見込み

2024年に4億2,460万米ドルと推定された口腔咽頭カンジダ症の世界市場は、2030年には4億8,920万米ドルに達し、分析期間2024～2030年のCAGRは2.4%で成長すると予測されます。本レポートで分析したセグメントの1つである偽膜性は、CAGR 2.0％を記録し、分析期間終了時には2億9,730万米ドルに達すると予測されます。紅斑性セグメントの成長率は、分析期間中CAGR 2.9%と推定されます。

米国市場は1億1,570万米ドルと推定、中国はCAGR4.5%で成長すると予測

米国の口腔咽頭カンジダ症市場は、2024年に1億1,570万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.5%として、2030年には予測市場規模9,310万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と1.8%と予測されています。欧州では、ドイツがCAGR 1.3%で成長すると予測されています。

世界の口腔咽頭カンジダ症市場- 主要動向と促進要因のまとめ

口腔咽頭カンジダ症がもはや単なる些細な機会感染ではなくなった理由とは？

一般的に口腔鵞口瘡として知られる口腔咽頭カンジダ症（OPC）は、主にカンジダ・アルビカンス、最近ではカンジダ・グラブラータやカンジダ・クルセイなどの非アルビカンス種によって引き起こされる粘膜の真菌感染症です。OPCはマイナーな疾患として軽視されがちであるが、現在では、特にHIV/AIDS、血液悪性腫瘍、臓器移植、化学療法やコルチコステロイド療法を受けている患者において、全身の免疫抑制の重要な指標とみなされています。免疫抑制レジメンと吸入コルチコステロイドの使用が増加しているため、リスク集団が拡大し、OPC管理に対する臨床的関心が高まっています。

さらに、抗真菌剤耐性菌、特にフルコナゾール曝露者の出現が治療プロトコルを複雑にしています。OPCは再発性であるばかりでなく、脆弱な患者では全身性カンジダ症とも関連しています。このため、強固な抗真菌薬スチュワードシップ、診断法の改善、そして耐性に強い新しい製剤の必要性が叫ばれています。さらに、高齢者、義歯装用者、糖尿病患者におけるOPCの負担は、世界の平均寿命の伸びと都市部の食生活の変化により増加しています。

より効果的な管理のために、診断法と局所治療法はどのように進化しているのか？

従来、OPCの診断は臨床検査と症候学的所見に依存していたが、種の多様性と耐性が増加しているため、より正確な診断ワークフローが必要とされています。KOH染色による顕微鏡検査、グラム染色、培養に基づくアッセイなどが依然として広く用いられています。しかし、正確な病原体の鑑別と抗真菌薬感受性プロファイリングのために、PCR法による菌種同定、MALDI-TOF質量分析、次世代シーケンサー（NGS）などの分子診断ツールが注目されています。

治療的には、ナイスタチン、クロトリマゾール、ミコナゾールなどの外用抗真菌薬が、合併症を伴わないOPCの第一選択薬として使用されています。しかし、中等症から重症例や再発例では、フルコナゾール、イトラコナゾール、ポサコナゾールなどのアゾール系全身薬が処方されることが多くなっています。難治性の感染症や耐性菌が関与する感染症にはエキノカンディン系抗真菌薬やアムホテリシンBが考慮されます。レザファンギンやイブレキサファンガープなどの新規抗真菌薬は、より広いスペクトラムを持ち、耐性率が低いため、開発中あるいは臨床使用の初期段階にあります。

なぜ抗真菌薬耐性と再発性感染症が技術革新を促すのか？

抗真菌剤耐性という世界の課題は、がん患者や移植患者におけるアゾール系抗真菌剤の広範な使用と長期間の予防投与に関連しており、OPC研究を形成する大きな力となっています。カンジダ・オーリスや特定の非アルビカンス菌種は多剤耐性を示すため、感染制御プロトコルを強化する必要があります。このため、殺菌性の代替薬、より優れた送達手段（粘着性ゲル、ロゼンジ、徐放性錠剤など）、および全身への曝露を最小限に抑えつつ有効性を高める併用療法が急務となっています。

特に免疫不全集団における再発性OPCは、抑制療法と長期維持戦略の需要を牽引しています。プロバイオティクス療法、宿主指向性免疫調節薬、CRISPRに基づく抗真菌技術などが早期から研究されています。これと並行して、高リスク群に予防的または補助的な防御を提供するために、カンジダ抗原を標的としたワクチン研究が進行中です。

口腔咽頭カンジダ症ソリューションの世界市場需要の原動力は？

口腔咽頭カンジダ症市場の成長の原動力は、世界の免疫抑制負担の増加、高齢化、免疫調節剤の普及、抗真菌剤耐性の上昇です。特に、診断の遅れが全身性の合併症を引き起こす可能性のある、資源が限られた環境におけるHIV陽性者や腫瘍患者のOPC有病率の増加が、主要な促進要因となっています。

医薬品の技術革新、真菌症管理のための公的医療費助成、外来治療モデルの台頭も市場拡大を支えています。さらに、歯科医療に対する意識の高まりと定期的な口腔ケアの浸透により、特にリスクの高い高齢者や糖尿病患者の早期発見と介入率が向上しています。

抗真菌剤耐性、再発性感染症、併存する危険因子がOPCの臨床的足跡を拡大し続ける中、正確な診断、安全で効果的な治療薬、予防的ケアの市場は持続的な成長を遂げるでしょう。今後の進歩は、病原体特異的治療と宿主指向の免疫学的戦略を組み合わせた統合管理アプローチにかかっています。

セグメント

タイプ（偽膜性、紅斑性、過形成）、治療法（抗真菌薬、免疫調整薬）、投与経路（経口、局所、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全36件）

  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Biocon Limited
  • Bristol Laboratories
  • Cidara Therapeutics Inc.
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • GlaxoSmithKline plc（GSK）
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novabiotics Limited
  • NovaDigm Therapeutics
  • Pfizer Inc.
  • SCYNEXIS, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35468

Global Oropharyngeal Candidiasis Market to Reach US$489.2 Million by 2030

The global market for Oropharyngeal Candidiasis estimated at US$424.6 Million in the year 2024, is expected to reach US$489.2 Million by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. Pseudomembranous, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$297.3 Million by the end of the analysis period. Growth in the Erythematous segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$115.7 Million While China is Forecast to Grow at 4.5% CAGR

The Oropharyngeal Candidiasis market in the U.S. is estimated at US$115.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$93.1 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Oropharyngeal Candidiasis Market - Key Trends & Drivers Summarized

Why Is Oropharyngeal Candidiasis No Longer Just a Minor Opportunistic Infection?

Oropharyngeal candidiasis (OPC), commonly known as oral thrush, is a fungal infection of the mucous membranes caused primarily by Candida albicans, and increasingly by non-albicans species such as Candida glabrata and Candida krusei. While often dismissed as a minor condition, OPC is now viewed as a critical indicator of systemic immunosuppression, particularly in patients with HIV/AIDS, hematologic malignancies, organ transplants, or those undergoing chemotherapy or corticosteroid therapy. The increasing use of immunosuppressive regimens and inhaled corticosteroids is broadening the at-risk population and driving higher clinical attention to OPC management.

Moreover, the emergence of antifungal resistance-especially among fluconazole-exposed individuals-is complicating treatment protocols. OPC is not only recurrent in nature but also linked to systemic candidiasis in vulnerable patients. This is prompting the need for robust antifungal stewardship, improved diagnostics, and newer, resistance-proof formulations. In addition, the burden of OPC among the elderly, denture wearers, and diabetic populations is growing due to rising global life expectancy and urban dietary transitions.

How Are Diagnostics and Localized Therapeutics Evolving for More Effective Management?

Conventional diagnosis of OPC relies on clinical inspection and symptomatic presentation, but rising species diversity and resistance necessitate more precise diagnostic workflows. Microscopy with KOH staining, Gram staining, and culture-based assays remain widely used. However, molecular diagnostic tools, such as PCR-based species identification, MALDI-TOF mass spectrometry, and next-generation sequencing (NGS), are gaining prominence for accurate pathogen differentiation and antifungal susceptibility profiling.

Therapeutically, topical antifungals such as nystatin, clotrimazole, and miconazole remain first-line agents for uncomplicated OPC. However, systemic azoles like fluconazole, itraconazole, and posaconazole are increasingly being prescribed in moderate to severe or recurrent cases. For refractory infections or those involving resistant species, echinocandins and amphotericin B are considered. Novel antifungals such as rezafungin and ibrexafungerp, which offer broader spectrum and lower resistance rates, are in development or early-stage clinical use.

Why Are Antifungal Resistance and Recurrent Infections Catalyzing Innovation?

The global challenge of antifungal resistance-linked to widespread azole use and prolonged prophylaxis in cancer and transplant patients-is a major force shaping OPC research. Candida auris and certain non-albicans species exhibit multidrug resistance and require heightened infection control protocols. This has created a pressing need for fungicidal alternatives, better delivery vehicles (e.g., mucoadhesive gels, lozenges, and slow-release tablets), and combination therapies that enhance efficacy while minimizing systemic exposure.

Recurrent OPC, especially in immunocompromised populations, is driving the demand for suppressive therapies and long-term maintenance strategies. Probiotic therapy, host-directed immunomodulators, and CRISPR-based antifungal technologies are under early exploration. In parallel, vaccine research targeting candidal antigens is underway to offer prophylactic or adjunctive protection in high-risk groups.

What’s Fueling the Global Market Demand for Oropharyngeal Candidiasis Solutions?

The growth in the oropharyngeal candidiasis market is driven by increasing global immunosuppression burden, aging populations, widespread use of immunomodulators, and rising antifungal resistance. A key driver is the growing prevalence of OPC among HIV-positive individuals and oncology patients, especially in resource-limited settings where delayed diagnosis can lead to systemic complications.

Pharmaceutical innovation, public health funding for mycosis management, and the rise of outpatient treatment models are also supporting market expansion. Additionally, the growing penetration of dental health awareness and regular oral care regimens is enhancing early identification and intervention rates, particularly in high-risk geriatric and diabetic populations.

As antifungal resistance, recurrent infections, and comorbid risk factors continue to expand the clinical footprint of OPC, the market for accurate diagnostics, safe and effective therapeutics, and preventive care will see sustained growth. Future advances will hinge on integrated management approaches combining pathogen-specific treatment with host-directed immunological strategies.

SCOPE OF STUDY:

The report analyzes the Oropharyngeal Candidiasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Pseudomembranous, Erythematous, Hyperplastic); Treatment (Anti-Fungal, Immune-Modulators); Administration Route (Oral, Topical, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Biocon Limited
  • Bristol Laboratories
  • Cidara Therapeutics Inc.
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • GlaxoSmithKline plc (GSK)
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novabiotics Limited
  • NovaDigm Therapeutics
  • Pfizer Inc.
  • SCYNEXIS, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oropharyngeal Candidiasis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Immunocompromised Conditions Drives Demand for Oropharyngeal Candidiasis Treatments
    • Expansion of Cancer Chemotherapy and Immunosuppressive Therapies Throws the Spotlight on Opportunistic Fungal Infections
    • Growth in HIV and Organ Transplant Patient Populations Spurs Need for Prophylactic and Curative Antifungals
    • OEM Innovation in Muco-Adhesive and Extended-Release Formulations Enhances Drug Retention and Efficacy
    • Increase in Resistance to Azoles and Polyenes Strengthens Business Case for Novel Antifungal Agents
    • OEM Development of Topical and Localized Drug Delivery Systems Reduces Systemic Side Effects and Improves Adherence
    • Regulatory Approvals of New-Generation Triazoles Expand Therapeutic Options in Refractory Candidiasis Cases
    • Surge in Geriatric and ICU Admissions Globally Drives Clinical Vigilance for Oral Fungal Infections
    • OEM Focus on Patient-Centric Formulations Like Lozenges and Mouthwashes Improves Accessibility in Pediatric and Geriatric Settings
    • Expansion of Oral Microbiome Research Supports Probiotic and Adjunctive Therapeutic Strategies
    • OEM Emphasis on Point-of-Care Testing and Rapid Fungal Diagnostics Enhances Treatment Timeliness
    • Increased Awareness in Oncology and Hematology Units Supports Early Candidiasis Screening Protocols
    • Growth in Telemedicine and Virtual Prescriptions Accelerates Access to Oral Antifungal Therapies
    • OEM Collaboration With Mycology Research Networks Drives Understanding of Pathogenesis and Drug Resistance
    • Focus on Antifungal Stewardship in Hospital Settings Supports Rational Prescribing and Cost Management
    • Rise in Denture Use and Oral Devices in Elderly Populations Expands Risk Profiles for Oropharyngeal Candidiasis
    • OEM Entry Into Generic and Biosimilar Formulations Enhances Price Competitiveness in Chronic Care Settings
    • Integration of Candidiasis Management in Multimorbidity Care Pathways Improves Patient Outcomes
    • Expansion of Antifungal Clinical Trials and Compassionate Use Programs Supports Innovation in Untreated Patient Segments
    • Challenges in Medication Compliance Among Immunocompromised Patients Propel Demand for Long-Acting Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oropharyngeal Candidiasis Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oropharyngeal Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pseudomembranous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pseudomembranous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pseudomembranous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erythematous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erythematous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Erythematous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hyperplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hyperplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hyperplastic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Anti-Fungal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Immune-Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Immune-Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Immune-Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Oropharyngeal Candidiasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 212: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Oropharyngeal Candidiasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Oropharyngeal Candidiasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION